Advertisement
Research Article| Volume 30, ISSUE 2, P145-150, July 15, 1991

Plasma phenylethylamine in schizophrenic patients

DOI:https://doi.org/10.1016/0006-3223(91)90168-L
Plasma phenylethylamine in schizophrenic patients
Previous ArticleA pilot placebo-controlled study of chronic m-CPP administration in Alzheimer's disease
Next ArticleDose dependent inhibition of REM sleep in normal volunteers by biperiden, a muscarinic antagonist
      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      Plasma samples were collected from 41 patients who met DSM-III criteria for schizophrenia and from 34 healthy controls. Phenylethylamine (PE) levels were determined using a gas chromatography-mass spectrometry negative chemical ionization method. PE was significantly higher in the schizophrenic patients compared with controls. There were no differences in PE between paranoid and nonparanoid patients. Plasma PE did not appear to be influenced by the severity of schizophrenic symptoms (rated by BPRS, SANS, and SAPS) or by the amount of dietary phenylalanine ingested within 24 hr of testing. Plasma PE did not correlate with current or past exposure to neuroleptic medication. It was not possible, however, to test individual patients during two periods when they were taking and not taking medication. Thus it is possible that neuroleptic exposure may have confounded the results. This study provides further evidence that PE excess may play a role in the etiology of schizophrenia but does not support previous studies which suggest that such an abnormality is limited to the paranoid subgroup.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • American Psychiatric Association
        ed 3. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association, Washington DC1980
        • Andreasen N.C.
        The Scale for the Assessment of Negative Symptoms (SANS).
        The University of Iowa, Iowa City, IA1983
        • Andreasen N.C.
        The Scale for the Assessment of Positive Symptoms (SAPS).
        The University of Iowa, Iowa City, IA1984
        • Beckmann H.
        • Reynolds G.P.
        • Sandler M.
        • et al.
        Phenylethylamine and phenylacetic acid in CSF of schizophrenics and healthy controls.
        Arch Psychiatr Nervenkr. 1982; 232: 463-471
        • Boulton A.A.
        Cerebral aryl alkyl aminergic mechanisms.
        in: Usdin E. Sandler M. Trace Amines and the Brain. Marcel Dekker, New York1976: 21-39
        • Boulton A.A.
        • Juorio A.V.
        • Paterson I.A.
        Phenylethylamine in the CNS: Effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission.
        J Neural Transm [Suppl]. 1990; 29: 119-129
        • Davis B.A.
        • Burden D.A.
        • Boulton A.A.
        Simultaneous analysis of twelve biogenic amine metabolites in plasma, cerebrospinal fluid and urine by capillary column gas chromatography-high resolution mass spectrometry with selected ion monitoring.
        J Chromatogr. 1986; 374: 227-238
        • Davis B.A.
        • Shrikhande S.
        • Paralikar V.P.
        • Hirsch S.R.
        • Durden D.A.
        • Boulton A.A.
        Phenylacetic acid in CSF and serum of Indian schizophrenic patients.
        Progr Neuro-Psychopharmacol Biol Psychiatry. 1991; 15: 41-47
        • Durden D.A.
        • Davis B.A.
        • Boulton A.A.
        Quantification of plasma phenylethylamine levels by electron capture negative ion gas chromatography-mass spectrometry of the N-acetyl-N-pentafluorobenzoyl derivative.
        Biomed Environ Mass Spectrom. 1991; (in press)
        • DeLisi L.E.
        • Wise C.D.
        • Bridge T.P.
        • et al.
        A probable neuroleptic effect on platelet monoamine oxidase in chronic schizophrenic patients.
        Psychiatry Res. 1981; 4: 95-107
        • Fischer E.
        • Heller B.
        Phenylethylamine as a neurohumoral agent in brain.
        Behav Neuropsychiatry. 1972; 4: 8-11
        • Folstein M.F.
        • Folstein S.E.
        • McHugh P.R.
        ‘Mini-mental stage’: A practical method for grading the cognitive state of patients for the clinician.
        J Psychiatr Res. 1975; 12: 189-198
        • Jeste D.V.
        • Doongaji D.R.
        • Panjwani D.
        • et al.
        Cross-cultural study of a biochemical abnormality in paranoid schizophrenia.
        Psychiatry Res. 1980; 3: 341-352
        • Jones R.S.G.
        • Boulton A.A.
        Interactions between p-tyramine, m-tyramine or B-phenylethylamine and dopamine on single neurons in the cortex and caudate nucleus of the rat.
        Can J Physiol Pharmacol. 1980; 58: 222-227
        • Magaro P.A.
        • Abrams L.
        • Cantrell P.
        The Maine scale of paranoid and nonparanoid schizophrenia: Reliability and validity.
        J Consult Clin Psychol. 1981; 49: 438-447
        • Oldendorf W.H.
        Brain uptake of radiolabeled amino acids, amines, and hexoses after arterial injection.
        Am J Physiol. 1971; 221: 1629-1639
        • Overall J.E.
        • Gorham D.R.
        The brief psychiatric rating scale (BPRS).
        Psychol Reports. 1962; 10: 799-812
        • Paterson I.A.
        • Boulton A.A.
        B-Phenylethylamine enhances single cortical neurone responses to noradrenalin in the rat.
        Brain Res Bull. 1988; 20: 173-177
        • Paterson I.A.
        • Juorio A.V.
        • Boulton A.A.
        B-Phenylethylamine: A modulator of catecholamine transmission in mammalian central nervous system.
        J Neurochem. 1990; 55: 1827-1837
        • Pennington J.A.
        • Church H.N.
        Bowes and Church's Food Values of Portions Commonly Used.
        J.B. Lippincott, Philadelphia1985
        • Potkin S.G.
        • Karoum F.
        • Chuang L.-W.
        • et al.
        Phenylethylamine in paranoid chronic schizophrenia.
        Science. 1979; 206: 470-471
        • Robins L.N.
        • Helzer J.E.
        • Croughan J.
        • Ratcliff K.S.
        National Institute of Mental Health Diagnostic Interview Schedule.
        Arch Gen Psychiatry. 1981; 38: 381-389
        • Sabelli H.C.
        • Fawcett J.
        • Gusovsky F.
        • et al.
        Clinical studies on the phenylethylamine hypothesis of affective disorder: Urine and blood phenylacetic acid and phenylalanine dietary supplements.
        J Clin Psychiatry. 1986; 47: 66-70
        • Szymanski H.V.
        • Naylor E.W.
        • Karoum F.
        Plasma phenylethylamine and phenylalanine in chronic schizophrenic patients.
        Biol Psychiatry. 1987; 22: 194-198
        • Tsuang M.T.
        • Winokur G.
        Criteria for sub-typing schizophrenia.
        Arch Gen Psychiatry. 1974; 31: 43-47
        • Yoshimoto S.
        • Kaku H.
        • Shimogawa S.
        • Watanabe A.
        • Nakagawa M.
        • Takahashi R.
        Urinary excretion and platelet monoamine oxidase activity in schizophrenia.
        Psychiatry Res. 1987; 21: 229-236

      Article info

      Publication history

      Received in revised form: February 5, 1991
      Received: September 19, 1990

      Identification

      DOI: https://doi.org/10.1016/0006-3223(91)90168-L

      Copyright

      © 1991 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect

      The content on this site is intended for healthcare professionals.


      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the Cookie Preference Center for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties.


      RELX